Supplementary Tables 1 - 5 and Figures 1 - 3 from Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Abstract

<p>Supplementary tables describe a comparison of half-lives of SYD983 in the different species (Table S1), PK details in mice (Table S2), PK details in tumor-bearing mice (Table S3), PK details in cynomolgus monkeys (Tables S4 and S5), Flow rates of SYD983 in RP-HPLC, HIC profile of SYD983 and SYD985 (Figure S1), Cytotoxicity of SYD983 versus SYD985 (Figure S2), and control staining for IHC of the tumors used in PDX (Figure S3).</p>